Expression of Enterocin A in Saccharomyces cerevisiae
- PMID: 40884739
- DOI: 10.1007/s12602-025-10686-0
Expression of Enterocin A in Saccharomyces cerevisiae
Abstract
Recombinant expression in the yeast Saccharomyces cerevisiae offers an alternative approach to developing large-scale production systems for class II bacteriocins from lactic acid bacteria, such as enterocin A, mundticin ST4SA and plantaricin 423. An important consideration for bacteriocin activity is disulphide bond formation: mature mundticin ST4SA has one, and plantaricin 423 and enterocin A each have two disulphide bonds. The native bacteriocin operon typically includes accessory proteins that facilitate disulphide bond formation, but this gene is absent in the enterocin A operon. In this study, the recombinant expression of a codon-optimised gene for enterocin A in S. cerevisiae, was compared to that for a codon-optimised plantaricin 423 and mundticin ST4SA, previously successfully expressed in S. cerevisiae. Shake flasks delivered more than twofold higher peptide EntA_Opt levels than PlaX_Opt and MunX_Opt, with even higher EntA_Opt expression levels in batch fermentations. However, the bacteriocin activity of plantaricin 423 was considerably lower than that of enterocin A and mundticin ST4SA. It is postulated that this could be a result of incorrect disulphide bond conformation due to the absence of the plantaricin accessory protein, PlaC, in S. cerevisiae. Nano-LC-MS/MS analysis showed various post-translational modifications for the peptides, with a greater proportion of EntA_Opt peptides with the correct disulphide bond conformation than for PlaX_Opt. This study demonstrated that S. cerevisiae is a promising host to produce recombinant class IIa bacteriocins, particularly enterocin A. However, the co-expression of accessory proteins should be investigated to improve the activity of recombinant plantaricin 423.
Keywords: Saccharomyces cerevisiae; Class IIa bacteriocins; Enterocin A; Mundticin ST4SA; Plantaricin 423.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing Interests: The authors declare no competing interests. Disclaimer: Opinions communicated and all conclusions arrived at are those of the authors and are not necessarily to be attributed to the NRF.
References
-
- Darbandi A, Asadi A, Mahdizade Ari M, Ohadi E, Talebi M, Halaj Zadeh M, Emamie AD, Ghanavati R, Kakanj M (2022) Bacteriocins: properties and potential use as antimicrobials. J Clin Lab Anal 36(1):e24093. https://doi.org/10.1002/jcla.24093 - DOI - PubMed
-
- Lozo J, Topisirovic L, Kojic M (2021) Natural bacterial isolates as an inexhaustible source of new bacteriocins. Appl Microbiol Biotechnol 105(2):477–492. https://doi.org/10.1007/s00253-020-11063-3 - DOI - PubMed
-
- Yi Y, Li P, Zhao F, Zhang T, Shan Y, Wang X, Liu B, Chen Y, Zhao X, Lü X (2022) Current status and potentiality of class II bacteriocins from lactic acid bacteria: structure, mode of action and applications in the food industry. Trends Food Sci Technol 120:387–401. https://doi.org/10.1016/j.tifs.2022.01.018 - DOI
-
- Lohans CT, Vederas JC (2012) Development of class IIa bacteriocins as therapeutic agents. Int J Microbiol 2012:1–13. https://doi.org/10.1155/2012/386410 - DOI
-
- Chikindas ML, Weeks R, Drider D, Chistyakov VA, Dicks LMT (2018) Functions and emerging applications of bacteriocins. Curr Opin Biotechnol 49:23–28. https://doi.org/10.1016/j.copbio.2017.07.011 - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources